Tesamorelin 10mg

Research

Scientific Research and Metabolic Effects of Tesamorelin

Tesamorelin is a stabilized GHRH analog with significant influence on metabolism via the growth hormone/IGF‑1 axis. In research models, this compound demonstrates the ability to affect visceral adipose tissue metabolism, triglyceride levels, and lipid profiles, combining anabolic and lipolytic mechanisms without substantially impacting glycemic homeostasis under controlled conditions.

Efficacy in Visceral Adipose Tissue Reduction

Tesamorelin has shown efficacy in reducing visceral adipose tissue (VAT) in individuals with HIV‑associated lipodystrophy. In two well‑designed, randomized, placebo‑controlled trials, a significant reduction in VAT was observed, whereas subcutaneous adipose tissue remained clinically unchanged. This VAT reduction was maintained over a prolonged period in patients who continued therapy, although VAT tended to accumulate again after discontinuation.
In addition, tesamorelin improved body‑composition measures, including reductions in trunk fat and waist circumference, as well as improvements in body‑image perception.

Impact on Non‑alcoholic Fatty Liver Disease (NAFLD)

Promising results have been observed with tesamorelin in reducing hepatic fat and limiting fibrosis progression in patients with HIV‑related NAFLD. In a placebo‑controlled trial, tesamorelin decreased hepatic fat fraction and improved gene‑expression scores associated with fibrosis, indicating a potential therapeutic role in NAFLD management in this population.
The peptide influences hepatic genetic pathways by increasing oxidative phosphorylation and reducing expression of inflammatory genes.

Effects on Adipose Tissue Quality

Beyond reducing total fat mass, tesamorelin has been shown to improve adipose tissue quality. Trials assessing fat density reported increases in the density of both subcutaneous adipose tissue and VAT, suggesting an improvement in fat quality independent of changes in absolute fat amount.

Cardiovascular and Metabolic Outcomes

The effect of tesamorelin on cardiovascular disease (CVD) risk has also been investigated, with data indicating a modest reduction in atherosclerotic risk factors over a 10‑year period. This reduction was primarily attributed to lower total‑cholesterol levels, even among participants who were already on lipid‑lowering therapy.
Tesamorelin was well tolerated, with no significant differences in glycemic parameters between treatment and placebo groups.

Neurocognitive and Health‑related Considerations

Although tesamorelin reduced waist circumference, its effects on neurocognitive impairment in obese individuals with HIV did not differ significantly from standard care, suggesting limited cognitive benefit. However, the peptide’s ability to increase IGF‑1 levels may open avenues for additional experimental applications that warrant further investigation.

References

• Falutz, J., et al. (2010). Effects of tesamorelin (TH9507), a growth hormone–releasing hormone analog, in HIV‑infected patients with excess abdominal fat: a pooled analysis of two multicenter, double‑blind, placebo‑controlled, phase 3 trials with safety‑extension data. The Journal of Clinical Endocrinology and Metabolism, 95(9), 4291–4304.
• Fourman, L., et al. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV‑associated NAFLD. JCI Insight, 5.
• Lake, J., et al. (2021). Tesamorelin improves fat quality independent of changes in fat quantity. AIDS, 35, 1395–1402.
• Grinspoon, S., et al. (2025). Impact of tesamorelin on cardiovascular risk‑prediction scores in phase‑3 trials: a subanalysis. Open Forum Infectious Diseases, 12.
• Ellis, R., et al. (2025). Effects of tesamorelin on neurocognitive impairment in abdominally obese individuals with HIV. The Journal of Infectious Diseases.

Scientific Reviewer

The content was reviewed by Dr. Ky H. Le, MD. Dr. Ky H. Le is a family physician in Aiea, Hawaii. He received his medical degree from St. George’s University School of Medicine and has practiced for over 20 years. He has expertise in the treatment of obesity, diabetes, hypertension, and high blood pressure, among other conditions. Dr. Ky H. Le accepts Medicare, Aetna, Humana, Blue Cross, and United Healthcare.

Ref.: https://health.usnews.com/doctors/ky-le-371599#expertise